06/09/2026
"It’s a very different conversation, a different tone."
For 15 years, Dan Pollyea, MD, MS, has been treating patients at the University of Colorado Anschutz Cancer Center, including those with a stubborn form of fast-growing adult leukemia called acute myeloid leukemia (AML). Over those years, Dr. Pollyea says, the relationships between clinicians and their AML patients have changed in a key way: These days, the relationships often last longer.
I'm thrilled to have the opportunity to tell the story of AML research and care at University of Colorado Anschutz, ongoing "team science" work that has led to new treatments and new hope for patients. Thanks for the assignment, Jessica Cordova! Thanks to Dr. Pollyea; Maria Amaya, MD, PhD; Craig Jordan, PhD; and James DeGregori, PhD, for sharing their insights. Thanks to Justin LeVett for the great photos and to Greg Glasgow for running my story in the new Cancer Center C3 magazine.
My latest story for the University of Colorado Anschutz School of Medicine.
At the CU Anschutz Cancer Center, a team science approach has resulted in new treatments for AML and new hope for patients—and the work continues.